11:39 AM EST - ProMetic Life Sciences Inc. : disclosed today during the Annual Meeting of the American Society of Nephrology (ASN) held in Philadelphia, new preclinical data on PBI-4050, an orally active anti-fibrotic drug currently in clinical trial stages. The animals in this model have concomitant type II diabetes and hypertension which mimic the conditions of several patients affected with Chronic Kidney Disease. ProMetic Life Sciences Inc.
shares T.PLI are trading down $0.02 at $1.96.
